

BBS6 (C-20): sc-49797

BACKGROUND

Bardet-Biedl syndrome (BBS) is a pleiotropic genetic disorder characterized by obesity, photoreceptor degeneration, polydactyly, hypogonadism, renal abnormalities, and developmental delay. BBS patients also have an increased risk of developing diabetes, hypertension, and congenital heart defects. BBS is a heterogeneous disorder; BBS genes map to eight genetic loci and encode eight proteins, BBS1-BBS8. Five BBS genes encode basal body or cilia proteins, suggesting that BBS is a ciliary dysfunction disorder. BBS6 is a Group II chaperonin-like protein that has evolved recently in animals from CCT/TRiC, a subunit of the eukaryotic chaperonin. Most of BBS6 localizes to the pericentriolar material (PCM), a proteinaceous tube surrounding centrioles. During interphase, BBS6 is restricted to the lateral surfaces of the PCM, but during mitosis, it relocates throughout the PCM and localizes to the intercellular bridge.

REFERENCES

1. Beales, P.L., et al. 2001. Genetic and mutational analyses of a large multi-ethnic Bardet-Biedl cohort reveal a minor involvement of BBS6 and delineate the critical intervals of other loci. *Am. J. Hum. Genet.* 68: 606-616.
2. Badano, J.L., et al. 2003. Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on Bardet-Biedl patients with two mutations at a second BBS locus. *Hum. Mol. Genet.* 12: 1651-1659.
3. Andersen, K.L., et al. 2005. Variation of the McKusick-Kaufman gene and studies of relationships with common forms of obesity. *J. Clin. Endocrinol. Metab.* 90: 225-230.
4. Dollfus, H., et al. 2005. Update on Bardet-Biedl syndrome. *J. Fr. Ophthalmol.* 28: 106-112.
5. Heon, E., et al. 2005. Ocular phenotypes of three genetic variants of Bardet-Biedl syndrome. *Am. J. Med. Genet. A* 132: 283-287.
6. Hichri, H., et al. 2005. Testing for triallelism: analysis of six BBS genes in a Bardet-Biedl syndrome family cohort. *Eur. J. Hum. Genet.* 13: 607-616.
7. Karmous-Benailly, H., et al. 2005. Antenatal presentation of Bardet-Biedl syndrome may mimic Meckel syndrome. *Am. J. Hum. Genet.* 76: 493-504.
8. Kim, J.C., et al. 2005. MKKS/BBS6, a divergent chaperonin-like protein linked to the obesity disorder Bardet-Biedl syndrome, is a novel centrosomal component required for cytokinesis. *J. Cell Sci.* 118: 1007-1020.
9. Nakane, T., et al. 2005. No evidence for triallelic inheritance of MKKS/BBS loci in Amish McKusick-Kaufman syndrome. *Am. J. Med. Genet. A* 138: 32-34.

CHROMOSOMAL LOCATION

Genetic locus: MKKS (human) mapping to 20p12.2; Mkks (mouse) mapping to 2 F3.

SOURCE

BBS6 (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of BBS6 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-49797 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-49797 X, 200 µg/0.1 ml.

APPLICATIONS

BBS6 (C-20) is recommended for detection of BBS6 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

BBS6 (C-20) is also recommended for detection of BBS6 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for BBS6 siRNA (h): sc-60257, BBS6 siRNA (m): sc-60258, BBS6 shRNA Plasmid (h): sc-60257-SH, BBS6 shRNA Plasmid (m): sc-60258-SH, BBS6 shRNA (h) Lentiviral Particles: sc-60257-V and BBS6 shRNA (m) Lentiviral Particles: sc-60258-V.

BBS6 (C-20) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of BBS6: 62 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200 or SK-N-SH cell lysate: sc-2410.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotting A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.